The current study highlights the potential benefits of pharmacologically increasing PUFAs and decreasing LCAC levels by methyl-GBB to improve insulin sensitivity and mitochondrial functionality as well as the cardioprotective effect of methyl-GBB in treating metabolic syndrome. This evidence concerns the gene INS and metabolic syndrome.